Latest & greatest articles for diclofenac

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on diclofenac or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on diclofenac and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for diclofenac

41. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial. (Abstract)

Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial. We aimed to investigate whether the addition of non-steroidal anti-inflammatory drugs or spinal manipulative therapy, or both, would result in faster recovery for patients with acute low back pain receiving recommended first-line care.240 patients with acute low back pain who had seen their general practitioner and had been (...) given advice and paracetamol were randomly allocated to one of four groups in our community-based study: diclofenac 50 mg twice daily and placebo manipulative therapy (n=60); spinal manipulative therapy and placebo drug (n=60); diclofenac 50 mg twice daily and spinal manipulative therapy (n=60); or double placebo (n=60). The primary outcome was days to recovery from pain assessed by survival curves (log-rank test) in an intention-to-treat analysis. This trial was registered with the Australian

2007 Lancet Controlled trial quality: predicted high

42. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. (Abstract)

Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Upper gastrointestinal safety of cyclo-oxygenase (COX)-2 selective inhibitors versus traditional non-steroidal anti-inflammatory drugs (NSAIDs) has not been assessed in trials that simulate standard clinical practice. Our aim was to assess the effects (...) of these drugs on gastrointestinal outcomes in a population that includes patients taking gastrointestinal protective therapy.A prespecified pooled intent-to-treat analysis of three double-blind randomised comparisons of etoricoxib (60 or 90 mg daily) and diclofenac (150 mg daily) in 34 701 patients with osteoarthritis or rheumatoid arthritis was done for upper gastrointestinal clinical events (bleeding, perforation, obstruction, or ulcer) and the subset of complicated events (perforation, obstruction

2007 Lancet

43. Topical diclofenac improved pain and physical function with no systemic side effects in primary osteoarthritis of the knee Full Text available with Trip Pro

Topical diclofenac improved pain and physical function with no systemic side effects in primary osteoarthritis of the knee Topical diclofenac improved pain and physical function with no systemic side effects in primary osteoarthritis of the knee | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Topical diclofenac improved pain and physical function with no systemic side effects in primary osteoarthritis of the knee Article Text

2006 Evidence-Based Medicine

44. The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis

The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis Pope J E, Prashker (...) M, Anderson J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of combination therapy with diclofenac (50 mg) and misoprostol (Arthrotec; 200 microg twice daily) for the treatment of patients with symptomatic

2004 NHS Economic Evaluation Database.

45. Single dose oral diclofenac for postoperative pain. Full Text available with Trip Pro

Single dose oral diclofenac for postoperative pain. Diclofenac is a benzene-acetic acid derivative that acts, like other NSAIDs, by inhibiting cyclo-oxygenase isoforms that mediate the body's production of the prostaglandins implicated in pain and inflammation. Diclofenac is widely available as a sodium or potassium salt. Diclofenac potassium tablets are known as 'immediate-release' diclofenac as absorption takes place in the gastrointestinal tract whereas 'delayed-release' (enteric-coated (...) ) diclofenac tablets resist dissolution until reaching the duodenum. An existing review showed that diclofenac was an effective treatment for acute postoperative pain but did not address the distinction between potassium and sodium salts due to lack of data. The aim of this update is to gather and add appropriate information published subsequently and, data permitting, examine any potential differences between the two different diclofenac formulations.To assess single dose oral diclofenac for the treatment

2004 Cochrane

46. Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam

Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Tavakoli M Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of meloxicam, a cyclo-oxygenase (COX)-2 selective inhibitor, versus diclofenac modified-release and piroxicam for 4 weeks, in the treatment of patients with osteoarthritis. The doses studied were 7.5 mg meloxicam once daily, 100 mg diclofenac

2003 NHS Economic Evaluation Database.

47. Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial

Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial von Scheele B, Pena B, Wong J, Niculescu L Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Valdecoxib (20 mg once daily), an oral cyclooxygenase (COX)-2-specific inhibitor, was compared with diclofenac (75 mg twice daily), a non-specific non-steroidal anti-inflammatory drug (NSAID

2003 NHS Economic Evaluation Database.

48. A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac

A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac Morant S V, Shield M J, Davey P G, MacDonald T M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology The misoprostol-diclofenac fixed combination preparation was compared with diclofenac and other prescribed nonsteroidal anti-inflammatory drugs (NSAIDs), to investigate the association between NSAIDs and admission to hospital for upper gastrointestinal (GI) haemorrhage and perforation and other upper GI events. Type of intervention Other: Secondary care. Economic study type Cost-effectiveness analysis. Study

2002 NHS Economic Evaluation Database.

49. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. Full Text available with Trip Pro

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. Current guidelines recommend that patients at risk for ulcer disease who require treatment for arthritis receive nonsteroidal antiinflammatory drugs (NSAIDs) that are selective for cyclooxygenase-2 or the combination of a nonselective NSAID with a proton-pump inhibitor. We assessed whether celecoxib would be similar to diclofenac plus omeprazole in reducing the risk (...) of recurrent ulcer bleeding in patients at high risk for bleeding.We studied patients who used NSAIDs for arthritis and who presented with ulcer bleeding. After their ulcers had healed, we randomly assigned patients who were negative for Helicobacter pylori to receive either 200 mg of celecoxib twice daily plus daily placebo or 75 mg of diclofenac twice daily plus 20 mg of omeprazole daily for six months. The end point was recurrent ulcer bleeding.In the intention-to-treat analysis, which included 287

2002 NEJM Controlled trial quality: uncertain

50. Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain

Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain Tarricone R, Martelli E, Parazzini F, Darba J, Le Pen C, Rovira J Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of two drug therapies, nimesulide and diclofenac, for the treatment of osteoarthritis (OA). Both drugs are nonsteroidal anti-inflammatory drugs (NSAIDs), which although beneficial in reducing pain and inflammation, may result in potentially serious consequences in terms

2001 NHS Economic Evaluation Database.

51. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. (Abstract)

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclo-oxygenase (COX), which leads to suppression of COX-1-mediated production of gastrointestinal-protective prostaglandins. Gastrointestinal injury is a common outcome. We compared the efficacy, safety, and tolerability of long-term therapy with celecoxib, a COX-1 sparing inhibitor of COX-2, with diclofenac, a non-specific COX (...) inhibitor.655 patients with adult-onset rheumatoid arthritis of at least 6 months' duration were randomly assigned oral celecoxib 200 mg twice daily or diclofenac SR 75 mg twice daily for 24 weeks. Anti-inflammatory and analgesic activity and tolerability were assessed at baseline, every 4 weeks, and at week 24. We assessed gastrointestinal safety by upper-gastrointestinal endoscopy within 7 days of the last treatment dose at centres where the procedure was available. Analysis was by intention-to-treat

2000 Lancet Controlled trial quality: predicted high

52. Single dose oral ibuprofen and diclofenac for postoperative pain. Full Text available with Trip Pro

Single dose oral ibuprofen and diclofenac for postoperative pain. Ibuprofen and diclofenac are two widely used non-steroidal anti-inflammatory (NSAID) analgesics. It is therefore important to know which drug should be recommended for postoperative pain relief. This review seeks to compare the relative efficacy of the two drugs, and also considers the issues of safety and cost.To assess the analgesic efficacy of ibuprofen and diclofenac in single oral doses for moderate to severe postoperative (...) allocation to treatment groups which compared either ibuprofen or diclofenac with placebo.Data were extracted by two independent reviewers, and trials were quality scored. Summed pain relief or pain intensity difference over four to six hours was extracted, and converted into dichotomous information yielding the number of patients with at least 50% pain relief. This was then used to calculate the relative benefit and the number-needed-to-treat (NNT) for one patient to achieve at least 50% pain

2000 Cochrane

53. Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis

Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis Kristiansen I S, Kvien T K, Nord E Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of diclofenac and misoprostol for the treatment of patients with rheumatoid arthritis (RA). Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised patients with RA

1999 NHS Economic Evaluation Database.

54. Economic evaluation of meloxicam (7.5mg) versus sustained release diclofenac (100mg) treatment for osteoarthritis: a cross-national assessment for France, Italy and the UK

Economic evaluation of meloxicam (7.5mg) versus sustained release diclofenac (100mg) treatment for osteoarthritis: a cross-national assessment for France, Italy and the UK Economic evaluation of meloxicam (7.5mg) versus sustained release diclofenac (100mg) treatment for osteoarthritis: a cross-national assessment for France, Italy and the UK Economic evaluation of meloxicam (7.5mg) versus sustained release diclofenac (100mg) treatment for osteoarthritis: a cross-national assessment for France (...) sustained release (SR) diclofenac (comparator, 100 mg/day). Type of intervention Treatment, palliative care. Economic study type Cost-effectiveness analysis. Study population The target population was that of patients with OA. Setting The setting was primary and secondary care. The economic analysis was conducted in France, Italy and the UK. Dates to which data relate Effectiveness evidence was from 1986 and an undated reference. Resource use dates ranged from 1989 to 1996. The price year was 1995-6

1997 NHS Economic Evaluation Database.

55. The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis

The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis Al J A, Michel B C, Rutten F F Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Diclofenac plus misoprostol (50 mg + 200micrograms twice (tid) or three times (tid) daily) versusdiclofenac alone (50 mg bid or tid) in the prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced ulcers in rheumatoid arthritis (RA) patients. Type

1996 NHS Economic Evaluation Database.